PLEGRIDY (Peginterferon Beta-1a) three-year data support long-term safety and efficacy in multiple sclerosis patients

Biogen has announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® (peginterferon beta-1a) over three years in people with relapsing-remitting multiple sclerosis (RRMS). The interim results from the first year of ATTAIN, a two-year extension study of the Phase 3 ADVANCE study, show the benefits of continued PLEGRIDY treatment on clinical outcomes and further define its safety profile. The study results will be presented at the 67th American Academy of Neurology's (AAN) Annual Meeting in Washington, DC.

"These data offer…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati